DILIrank: The largest reference drug list ranked by the risk for developing drug-induced liver injury in humans

Drug Discovery Today

Volumn 21, Issue 4, 2016, Pages 648-653

  Chen, Minjun ^a   Suzuki, Ayako ^b   Thakkar, Shraddha ^a   Yu, Ke ^a   Hu, Chuchu ^a   Tong, Weida ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ANTIFUNGAL AGENT; ANTIGOUT AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; CENTRAL STIMULANT AGENT; IMMUNOSTIMULATING AGENT; INTERFERON; MACROLIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEIN KINASE INHIBITOR; TRIAZOLE DERIVATIVE; DRUG;

DATA ANALYSIS; DRUG DATABASE; HUMAN; REGISTER; REVIEW; RISK FACTOR; TOXIC HEPATITIS; CLASSIFICATION; DRUG LABELING; FACTUAL DATABASE; RISK;

CHEMICAL AND DRUG INDUCED LIVER INJURY; DATABASES, FACTUAL; DRUG LABELING; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK;

EID: 84960323993     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.02.015     Document Type: Review

References (46)

1. V.Y. Soldatow, and et al. In vitro models for liver toxicity testing Toxicol. Res. 2 2013 23 39
2. R. Paules Phenotypic anchoring: linking cause and effect Environ. Health Perspect. 111 2003 A338
3. M. Chen, and et al. Liver Toxicity Knowledge Base (LTKB) - a systems approach to a complex endpoint Clin. Pharmacol. Ther. 95 2013 409 412
4. M. Chen, and et al. Predicting idiosyncratic drug-induced liver injury-some recent advances Expert Rev. Gastroenterol. Hepatol. 8 2014 721 723
5. H. Olson, and et al. Concordance of the toxicity of pharmaceuticals in humans and in animals Regul. Toxicol. Pharmacol. 32 2000 56 67
6. N. Kaplowitz Idiosyncratic drug hepatotoxicity Nat. Rev. Drug Discov. 4 2005 489 499
7. M. Chen, and et al. Toward predictive models for drug-induced liver injury in humans: are we there yet? Biomark. Med. 8 2014 201 213
8. M. Chen, and et al. FDA-approved drug labeling for the study of drug-induced liver injury Drug Discov. Today 16 2011 697 703
9. C. Lammert, and et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals Hepatology 47 2008 2003 2009
10. Z. Weng, and et al. A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications Oncotarget 6 2015 17031 17038
11. J.J. Xu, and et al. Cellular imaging predictions of clinical drug-induced liver injury Toxicol. Sci. 105 2008 97 105
12. N. Greene, and et al. Developing structure-activity relationships for the prediction of hepatotoxicity Chem. Res. Toxicol. 23 2010 1215 1222
13. F. Gustafsson, and et al. A correlation between the in vitro drug toxicity of drugs to cell lines which express human P450s and their propensity to cause liver injury in humans Toxicol. Sci. 137 2013 189 211
14. A. Suzuki, and et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work Drug Saf. 33 2010 503 522
15. C.J. Ursem, and et al. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities Regul. Toxicol. Pharmacol. 54 2009 1 22
16. A.D. Rodgers, and et al. Modeling liver-related adverse effects of drugs using knearest neighbor quantitative structure-activity relationship method Chem. Res. Toxicol. 23 2010 724 732
17. X. Zhu, and N.L. Kruhlak Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data Toxicology 321 2014 62 72
18. M.Z. Sakatis, and et al. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds Chem. Res. Toxicol. 25 2012 2067 2082
19. S. Murphy, and R. Roberts 'Black box' 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk J. Allergy Clin. Immunol. 117 2006 34 39
20. A. Roth, and T. Singer The application of 3D cell models to support drug safety assessment: opportunities & challenges Adv. Drug Deliv. Rev. 69 2014 179 189
21. M. Chen, and et al. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs Toxicol. Sci. 136 2013 242 249
22. S.-H. Huang, and et al. Developing a QSAR model for hepatotoxicity screening of the active compounds in traditional Chinese medicines Food Chem. Toxicol. 78 2015 71 77
23. M. Chen, and et al. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury Hepatology 58 2013 388 396
24. M.D. Aleo, and et al. Human drug-induced liver injury severity is highly associated to dual inhibition of liver mitochondrial function and bile salt export pump Hepatology 60 2014 1015 1022
25. F.A. Atienzar, and et al. Predictivity of dog co-culture model, primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humans Toxicol. Appl. Pharmacol. 275 2014 44 61
26. H. Garside, and et al. Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes Toxicol. In Vitro 28 2014 171 181
27. S.R. Khetani, and et al. The use of micropatterned co-cultures to detect compounds that cause drug induced liver injury in humans Toxicol. Sci. 132 2012 107 117
28. F. Shah, and N. Greene Analysis of Pfizer compounds in EPA's ToxCast chemicals-assay space Chem. Res. Toxicol. 27 2013 86 98
29. M. Chen, and et al. An improved testing strategy to predict risk for drug-induced liver injury in humans using high-content screening assays and the 'rule-of-two' model Arch. Toxicol. 88 2014 1439 1449
30. T. Tomida, and et al. Multiparametric assay using HepaRG cells for predicting drug-induced liver injury Toxicol. Lett. 236 2015 16 24
31. A. Hill, and et al. Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development Drug Metab. Rev. 44 2012 127 140
32. W. Mattes, and et al. Detection of hepatotoxicity potential with metabolite profiling (metabolomics) of rat plasma Toxicol. Lett. 230 2014 467 478
33. D. Jennen, and et al. Drug-induced liver injury classification model based on in vitro human transcriptomics and in vivo rat clinical chemistry data Syst. Biomed. 2 2014 63 70
34. M. Zhang, and et al. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans? Chem. Res. Toxicol. 25 2012 122 129
35. A. Regev Drug-induced liver injury and drug development: industry perspective Semin. Liver Dis. 34 2014 227 239
36. M. García-Cortés, and et al. Causality assessment methods in drug induced liver injury: strengths and weaknesses J. Hepatol. 55 2011 683 691
37. N. Chalasani, and et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study Gastroenterology 148 2015 1340 1352
38. J.H. Hoofnagle, and et al. LiverTox: a website on drug-induced liver injury Hepatology 57 2013 873 874
39. E.S. Björnsson, and J.H. Hoofnagle Categorization of drugs implicated in causing liver injury: critical assessment based upon published case reports Hepatology 63 2016 590 603
40. K.E. Lasser, and et al. Timing of new black box warnings and withdrawals for prescription medications JAMA 287 2002 2215 2220
41. S.A. Rivkees 63 years and 715 days to the 'boxed warning': unmasking of the propylthiouracil problem Int. J. Pediat. Endocrinol. 2010 2010 658267
42. J.A. Knight Drug-induced hepatic injury: Marplan hepatitis Am. J. Psychiatry 118 1961 73
43. D. Larrey, and M.P. Ripault Hepatotoxicity of psychotropic drugs and drugs of abuse N. Kaplowitz, L.D. DeLeve, Drug-Induced Liver Disease 3rd edn 2013 Elsevier 443 462
44. M.I. Lucena, and et al. Antidepressant-induced hepatotoxicity Expert Opin. Drug Safety 2 2003 249 262
45. R.J. Andrade, and et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period Gastroenterology 129 2005 512 521
46. W. Lewis, and et al. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective Nat. Rev. Drug Discov. 2 2003 812 822